HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin-Reference-Cited by-同舟云学术

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

Published:2022-02-02 Issue:12 Volume:41 Page:1701-1717
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Biondini Marco,Kiepas Alex,El-Houjeiri Leeanna,Annis Matthew G.,Hsu Brian E.,Fortier Anne-Marie,Morin Geneviève,Martina José A.,Sirois Isabelle,Aguilar-Mahecha Adriana,Gruosso Tina,McGuirk Shawn^ORCID,Rose April A. N.,Tokat Unal M.^ORCID,Johnson Radia M.,Sahin Ozgur^ORCID,Bareke Eric^ORCID,St-Pierre Julie,Park Morag^ORCID,Basik Mark,Majewski Jacek^ORCID,Puertollano Rosa,Pause Arnim,Huang Sidong^ORCID,Keler Tibor,Siegel Peter M.^ORCID

Funder

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-022-02206-z.pdf

Reference76 articles.

1. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.

2. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–9.

3. Damaskos C, Garmpi A, Nikolettos K, Vavourakis M, Diamantis E, Patsouras A, et al. Triple-negative breast cancer: the progress of targeted therapies and future tendencies. Anticancer Res. 2019;39:5285–96.